View The Document

Accession Number:

AD1155711

Title:

Sensitization of Therapeutic-Resistant Pancreatic Cancer by Cancer Cell-Specific Drug Delivery

Author(s):

• Pandol, Stephen
• Tomlinson, James S.
• Chung, Leland W.

Author Organization(s):

• University of California, Los Angeles

Report Date:

2021-09-01

Abstract:

In the third year of this three-year project, we have completed most of the tasks following the timeline of our Statement of Work. Although the COVID-19 pandemic has severely affected progress of the project during this year by interrupting some of the proposed studies, we are excited to report our studies performed confirms that HMCD-SIM demonstrates cytotoxic activity in pancreatic cancer cells in vitro and furthermore demonstrates tumor growth inhibition in pancreatic cancer xenografts. These experimental data obtained strongly support our main hypothesis that HMCD-SIM is a potential potent new anti-tumor agent drug for pancreatic cancer. This was our main goal of our third year of experimentation.

Document Type:

Conference:

Journal:

Pages:

11

File Size:

0.77MB

Contracts:

Grants:

Descriptors:

Identifiers:

• Pancreatic ductal adenocarcinoma
• heptamethine carbocyanine
• simvastatin
• conjugate
• anti-tumor therapy
• chemotherapeutic sensitization

SubjectCategory:

• Biological and Medical Sciences

Distribution Statement:

Approved For Public Release

View The Document